Micro Cap Biotechnology
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
|
VIVS
276
VivoSim Labs
VIVS
$1.46M
| $1.46M | $0.4189 | 6.91% |
|
|
PPBT
277
Purple Biotech
PPBT
$1.33M
| $1.33M | $1.43 | 2.88% |
|
|
SCNI
278
Scinai Immunotherapeutics
SCNI
$1.19M
| $1.19M | $0.2300 | 6.92% |
|
|
VBIO
279
Valion Bio
VBIO
$951K
| $951K | $0.2970 | 3.85% |
|
280
VYNE Therapeutics
VYNE
$340K
| $340K | $0.5090 | 44.9% |
|
Micro Cap Biotechnology Stocks at a Glance
Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.
There are 280 micro cap Biotechnology stocks — companies in the Biotechnology industry with a market cap under $250M — worth a combined $19.2B.
The largest by market cap are Agenus (AGEN) at $249M, Fulcrum Therapeutics (FULC) at $248M and ProQR Therapeutics (PRQR) at $243M.
Among institutional investors, Atrium Therapeutics (RNA) drew the most net new fund positions in Q1 2026: 162 funds opened new positions.
- Combined market cap: $19.2B across 280 stocks.
- Micro Cap: market cap under $250M.
- Largest constituent: Agenus (AGEN), $249M market cap.
- Most net new fund positions in Q1 2026: Atrium Therapeutics (RNA), +162 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q1 2026.